Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris (OPAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02815332
Recruitment Status : Completed
First Posted : June 28, 2016
Last Update Posted : April 14, 2017
Sponsor:
Information provided by (Responsible Party):
BioPharmX, Inc.

Tracking Information
First Submitted Date  ICMJE June 24, 2016
First Posted Date  ICMJE June 28, 2016
Last Update Posted Date April 14, 2017
Study Start Date  ICMJE August 2016
Actual Primary Completion Date March 24, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 27, 2016)
Change in inflammatory lesion counts [ Time Frame: 12 weeks ]
Absolute mean change from baseline in inflammatory lesion counts
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02815332 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 27, 2016)
Reduction in IGA [ Time Frame: 12 weeks ]
Proportion of subjects with at least a two-grade reduction in IGA from baseline
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
Official Title  ICMJE A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris
Brief Summary

This is a 12-week, multi-center, double-blind, randomized, three-arm, vehicle-controlled study.

Subjects will be randomized (1:1:1) to 1% or 2 % BPX-01 gel, or vehicle. Subjects will apply 1g of the gel as a thin film to the entire face at least 30 minutes before bedtime each night for 12 weeks. Lesion counts, IGA, and Patient-Reported Outcomes (PGI-S and PGI-I) will be performed to assess efficacy.

Blood draws will be collected at baseline (Day 0), and at Weeks 4 and 12 to evaluate the level of minocycline in plasma. Safety will be assessed with the vital signs, brief physical examination, clinical laboratory tests, cutaneous tolerance score, incidence of minocycline-induced skin hyperpigmentation, incidence of visual disturbances and/or headaches suggestive of pseudotumor cerebri, and collection of adverse events.

Detailed Description

This is a phase 2b, randomized, double-blind, vehicle-controlled study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris.

Study Population: Approximately 225 male or female subjects aged between 9 and 40 years with moderate to severe inflammatory non-nodular acne vulgaris will be included in this study.

Number of Sites: Approximately 15 centers from the United States will participate in this study.

Study Duration: Overall study duration is expected to be approximately 24 weeks (6 months). The study duration for individual subjects is approximately 16 weeks (including the screening period).

Hypothesis: BPX-01 improves disease condition in subjects with moderate to severe inflammatory non-nodular acne vulgaris compared with vehicle.

Objectives:

Primary:

  • To evaluate the efficacy of BPX-01 minocycline 1% or 2% topical gel in the treatment of inflammatory non-nodular acne vulgaris

Secondary:

  • To evaluate the plasma level of minocycline after once daily application of 1% or 2% BPX 01 topical gel
  • To evaluate the safety of BPX-01 minocycline 1% or 2% topical gel

Endpoints:

Primary Efficacy Endpoint:

  • Absolute mean change from baseline in inflammatory lesion counts at Week 12

Secondary Efficacy Endpoint:

  • Proportion of subjects with at least a two-grade reduction in IGA at Week 12
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Acne Vulgaris
Intervention  ICMJE
  • Drug: BPX-01 1% Minocycline Topical Gel
    Approximately 1 gram applied once daily for 12 weeks
    Other Name: BPX-01 Topical Gel
  • Drug: BPX-01 2% Minocycline Topical Gel
    Approximately 1 gram applied once daily for 12 weeks
    Other Name: BPX-01 Topical Gel
  • Drug: BPX-01 Vehicle Topical Gel
    Approximately 1 gram applied once daily for 12 weeks
    Other Name: BPX-01 Vehicle Gel
Study Arms  ICMJE
  • Placebo Comparator: BPX-01 Vehicle Topical Gel
    Approximately 1 gram applied once daily for 12 weeks
    Intervention: Drug: BPX-01 Vehicle Topical Gel
  • Experimental: BPX-01 1% Minocycline Topical Gel
    Approximately 1 gram applied once daily for 12 weeks
    Intervention: Drug: BPX-01 1% Minocycline Topical Gel
  • Experimental: BPX-01 2% Minocycline Topical Gel
    Approximately 1 gram applied once daily for 12 weeks
    Intervention: Drug: BPX-01 2% Minocycline Topical Gel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 27, 2016)
225
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE March 24, 2017
Actual Primary Completion Date March 24, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female subjects aged between 9 and 40 years of age.
  2. Subjects do not have any medical conditions, other than acne vulgaris, that in the opinion of the investigator, put the subject at unacceptable risk or could interfere with study assessments or integrity of the data.
  3. Moderate to severe inflammatory non-nodular acne vulgaris.
  4. Female subjects of childbearing potential (including pre-puberty) are willing to use effective contraceptive method for at least 28 days before baseline (Day 0) and at least 28 days after the last study product administration or have a sterilized or same-sex partner for the duration of the study.
  5. Treatment with hormonal therapy must be on a stable dose and frequency for at least 12 weeks before baseline (Day 0) and must remain stable throughout the study.
  6. Subjects who use make-up, facial moisturizers, creams, or lotions, cleansers and/or sunscreens must have used the same product brands/types for a minimum period of 14 days prior to baseline (Day 0), must agree not to change brand/type or frequency of use throughout the study and must agree not to use make-up, facial moisturizers, creams, or lotions, cleansers and/or sunscreens on the clinic visit days before the visit.
  7. Subjects must be capable of giving informed consent and the written informed consent must be obtained prior to any study-related procedures. Subject under 18 years of age must sign an assent form, and their parent(s) or legal representative must have read and signed the informed consent form prior to any study-related procedures.

Exclusion Criteria:

  1. Female subject who is breastfeeding, pregnant or who is planning a pregnancy during the study.
  2. Have acne fulminans or conglobata, or nodulocystic acne.
  3. Have a history of skin disease, presence of skin condition, or excessive facial hair that, in the opinion of the investigator, would interfere with the study.
  4. Have a history of cancer or lymphoproliferative disease other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
  5. Have a history of minocycline-induced hepatitis, minocycline-induced arthritis, minocycline-induced lupus or minocycline/tetracycline-induced pseudotumor cerebri.
  6. Presence of minocycline-induced hyperpigmentation at screening or baseline (Day 0).
  7. Presence of visual disturbances and/or headaches suggestive of pseudotumor cerebri at screening or baseline (Day 0).
  8. Have a clinical chemistry or hematology laboratory value that is abnormal at the screening visit and that is considered clinically significant by the investigator.
  9. Has an ALT or AST at screening greater than or equal to 2 times the upper limit of normal.
  10. Have used on the face an over-the-counter (OTC) topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, salicylic acid, α-hydroxy/glycolic, antibacterial/antiseptic soap or wash within 14 days prior to baseline (Day 0).
  11. Have used prescription topical retinoid (e.g. tretinoin, tazarotene, adapalene) or antimicrobials (e.g. clindamycin, erythromycin) or other prescription topical medications for the treatment of acne vulgaris within 28 days of baseline (Day 0).
  12. Have used systemic antibiotics or other systemic anti-acne drugs not mentioned in the exclusion criteria within 28 days of baseline (Day 0).
  13. Have used oral, intranasal, or injectable corticosteroids within 28 days of baseline (Day 0) or require them during the study. Inhaled corticosteroids for stable medical conditions are allowed.
  14. Have received an investigational therapy (including investigational drug or procedure) within 28 days of baseline (Day 0) or plan to use one during the study.
  15. Have had a facial procedure (e.g. chemical peel, laser, microdermabrasion) within 8 weeks of baseline (Day 0).
  16. Have excessive sun exposure, is planning a trip to a sunny climate or used tanning booths within 28 days prior to baseline (Day 0) or is not willing to minimize natural and artificial sunlight exposure during the study.
  17. Have received photodynamic therapy or phototherapy with blue or red light within 12 weeks of baseline (Day 0).
  18. Have used androgen receptor blockers (such as spironolactone or flutamide) within 12 weeks of baseline (Day 0).
  19. Have used drospirenone, chlormadinone acetate, and cyproterone acetate within 26 weeks of baseline (Day 0).
  20. Have used oral retinoid (e.g., isotretinoin) within 52 weeks prior to baseline (Day 0) or vitamin A supplements greater than 10,000 U/d within 26 weeks of baseline (Day 0).
  21. History of clinically significant drug or alcohol abuse in the last year prior to baseline (Day 0) as judged by the investigator.
  22. Has known or suspected allergy to minocycline, tetracycline-class antibiotics or any component of the investigational product.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 9 Years to 40 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02815332
Other Study ID Numbers  ICMJE BPX-01-C03
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Responsible Party BioPharmX, Inc.
Study Sponsor  ICMJE BioPharmX, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: AnnaMarie Daniels Sponsor (BioPharmX)
PRS Account BioPharmX, Inc.
Verification Date April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP